It was a packed room at the Folsom street Foundry in downtown San Francisco this afternoon as folks poured in to take a look at the latest improvements from Indibio’s 0.33 demo day.
The accelerator’s demo day has grown so large we’re now live streaming it on TechCrunch.
but it surely was only a couple years ago that the one pure biotech accelerator launched out of SOS Ventures. Many accelerators and project corporations have started to take a keen passion in the house in view that then, but Indiebio continues to be the one many appear to in the business for bizarre and interesting ideas like 3D printed animal parts, egg whites type micro bugs and bioreactors to make higher beer.
The 0.33 highly charming experience was no exception, with startups supplying wild concepts on stage like mushroom leather-based clothing, a Zika-detecting tool the scale of a stick of gum and human breast milk made in a lab. right here we existing to you all 15 startups in IndieBio’s 1/3 batch:
here we existing to you all 15 startups in IndieBio’s 1/3 batch:
Mycoworks– Mycoworks uses mushrooms to create natural choices to leather. Their supplies are performance engineered, animal-free, sustainable, and price-competitive, and the corporate says it has three partnerships in sneakers and fashion. right through demo day, they unveiled their cow-sized “mycoleather,” growing the identical of a whole cowhide within three weeks.
SyntheX Labs– SyntheX makes use of one thing known as “synthetic lethality” to deal with right now incurable cancers. The startup claims its platform can check greater than 10 billion protein variations in one petri dish to create new therapeutics. SynthX says it’s speaking to multiple pharmaceutical firms and has promising data, together with a new, developed cancer-killing mechanism they’re hoping to post in the following couple of months.
Ava Labs– Ava promises to clone high-finish wines without the usage of grapes. It does this by way of analyzing molecular profiles of make a choice wines and reconstructing them as a bioidentical healthy to costlier wines, like an $ 11,000 1973 Chateau Montelena Chardonnay. Ava sold out in their pre-sale cloned wines, already raised $ 2.5M dollars and plan to begin transport wines to their first consumers within six months.
Knox clinical Diagnostics– Knox needs to prevent asthma assaults in youngsters before they begin. It has created what it says is a health facility-level bronchial asthma administration tool that can give predictive insights at dwelling. They performed an eighty affected person learn about in asthma patients thus far and have began a 500 affected person find out about with united states of america, which they plan to roll out with their product, publish-FDA approval, by means of Spring of 2017.
AstRoNA Biotechnologies– meals poisoning is a significant global difficulty these days with over 1 in 6 people getting food poisoning once a year. AstRoNA got here up with a handheld detector for probably contaminated foods that can be deployed on-website at each section of meals production. they are saying you should use the instrument “from box to desk,” giving labs correct outcomes within one hour. AstroNA has also established pilot applications with four food companies. It hopes to lift 1.7 million for an initial roll-out large scale gross sales by way of the top of the 12 months.
BioNascent– BioNascent is making what they are saying is a bioidentical breast milk formula for babies who aren’t breastfed. It does this by means of making proteins found in human breast milk they hope can present an various to dairy-primarily based baby formulation. they say they have already got a supplier relationship to roll out their first product, focused on the lab research market followed through a plan for approval within three years with the aid of the FDA.
Amaryllis Nucleics– Amaryllis desires to assist researchers by using accelerating RNA discoveries. Amaryllis says it could halve the time and scale back the price of RNA sequencing by way of eight-fold to accelerate most cancers diagnostics, pharmaceutical construction, and food security. Amaryllis says it has closed over $ 250k in gross sales to this point and targets to promote internationally by next year.
MiraculeX– MiraculeX desires to develop the subsequent era of healthy and attractive protein sweeteners by means of boosting vegetation producing these sweeteners. The staff behind the startup says its natural proteins have zero calories, no bitter flavor, and taste better than sugar. MiraculeX plans to roll out its first protein sweetener with the aid of the end of this 12 months and hopes to unlock more protein-based sweeteners with the aid of next 12 months.
OneSkin technologies– OneSkin has developed what it says is actual human skin in the lab. OneSkin says it could possibly replicate pores and skin via ethnicity and age to improve a line of personalised skin care products. The startup additionally claims to have centered its first purchaser relationship with a big cosmetics company and it goals to roll out personalized skincare with its own line of anti-getting older cosmetics within a 12 months.
Willow Cup– Willow Cup is creating a line of plant-based totally milk products, beginning with latte foam. The startup hopes to disrupt the plant-based milk trade the use of a patented plant protein library. It also says it has formed relationships and gross sales with 10 distributors inside San Francisco so far and is taking a look to push into the nationwide market.
Endura Bio– California is still in a drought and water is valuable in the Golden State. Endura is growing an agricultural spray to prompt drought tolerance in crops to cut back water use with the aid of 33 % and is presently conducting box trials in California to test the technology.
Ardra– pure flavors and fragrances is the fastest rising class in a market price over $ 23 billion globally. Ardra claims its enzyme technology allows them to make flavors at a lower price and better margin than every other natural alternative. Ardra says it was once able to get to industrial yield numbers of their first product inside their first 4 months, slashing years off of the product building cycle.
mFluidX– Zika is a scary disease linked to microencephaly in toddlers with mother’s who contract it whereas pregnant. Brazil is a company highly infested with the disease proper as the arena is headed there this August for the summer Olympic video games. mFluidX has created a diagnostic chip the scale of a % of gum to exchange bulky laboratory instrumentation for DNA / RNA diagnosis and claims it might notice Zika in the field. mFluidX says its energy-free disposable chip costs one thousand-instances lower than current know-how and can be abruptly deployed to diagnose infectious diseases any place. Its first partnership is with the virologist who identified Zika in Brazil.
Jungla– Jungla claims to be the sector’s best predictor for versions of unknown magnitude within the genome, starting with cancers by way of combining computing device learning with proprietary protein function maps. The startup says it has a partnership within the works with a widely known sequencing firm, some of the top genomic diagnostics firms and some of the largest coronary heart hospitals in the U.S.
Qidni Labs– Qidni is an implantable synthetic kidney. The startup just accomplished its first successful pre-medical trial in a pig and plans to complete pre-clinical trials subsequent 12 months and get it to market within the next five years.
This entry handed through the Full-text RSS service – if that is your content material and you’re reading it on any individual else’s website online, please learn the FAQ at fivefilters.org/content material-handiest/faq.php#publishers.
really useful article from FiveFilters.org: Most Labour MPs within the UK Are Revolting.
Startups – TechCrunch